CHA Vaccine Institute Co. Ltd.
Cha Vaccine Research Institute Co., Ltd., a research-oriented biotechnology company, researches and develops a range of vaccine products for infectious and chronic diseases. Its product pipeline includes HBV vaccine that is in Phase IIb planning for the prevention of hepatitis B; Adjuvanted HBV vaccine that is in Phase I/IIa for the treatment of chronic hepatitis B; and VZV Vaccine, which is in p… Read more
CHA Vaccine Institute Co. Ltd. (261780) - Total Assets
Latest total assets as of September 2025: ₩39.82 Billion KRW
Based on the latest financial reports, CHA Vaccine Institute Co. Ltd. (261780) holds total assets worth ₩39.82 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
CHA Vaccine Institute Co. Ltd. - Total Assets Trend (2019–2024)
This chart illustrates how CHA Vaccine Institute Co. Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
CHA Vaccine Institute Co. Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
CHA Vaccine Institute Co. Ltd.'s total assets of ₩39.82 Billion consist of 94.4% current assets and 5.6% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 21.4% |
| Accounts Receivable | ₩156.33 Million | 0.3% |
| Inventory | ₩0.00 | 0.0% |
| Property, Plant & Equipment | ₩1.12 Billion | 2.4% |
| Intangible Assets | ₩174.67 Million | 0.4% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how CHA Vaccine Institute Co. Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CHA Vaccine Institute Co. Ltd.'s current assets represent 94.4% of total assets in 2024, a decrease from 94.6% in 2019.
- Cash Position: Cash and equivalents constituted 21.4% of total assets in 2024, up from 0.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is property, plant & equipment at 2.4% of total assets.
CHA Vaccine Institute Co. Ltd. Competitors by Total Assets
Key competitors of CHA Vaccine Institute Co. Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
CHA Vaccine Institute Co. Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - CHA Vaccine Institute Co. Ltd. generates 0.01x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - CHA Vaccine Institute Co. Ltd. is currently not profitable relative to its asset base.
CHA Vaccine Institute Co. Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.82 | 60.10 | 4.51 |
| Quick Ratio | 1.82 | 60.10 | 4.51 |
| Cash Ratio | 0.00 | 0.00 | 0.57 |
| Working Capital | ₩16.73 Billion | ₩ 47.70 Billion | ₩ 18.02 Billion |
CHA Vaccine Institute Co. Ltd. - Advanced Valuation Insights
This section examines the relationship between CHA Vaccine Institute Co. Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.12 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 4.7% |
| Total Assets | ₩47.25 Billion |
| Market Capitalization | $34.14 Million USD |
Valuation Analysis
Below Book Valuation: The market values CHA Vaccine Institute Co. Ltd.'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: CHA Vaccine Institute Co. Ltd.'s assets grew by 4.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for CHA Vaccine Institute Co. Ltd. (2019–2024)
The table below shows the annual total assets of CHA Vaccine Institute Co. Ltd. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩47.25 Billion | +4.72% |
| 2023-12-31 | ₩45.12 Billion | -26.12% |
| 2022-12-31 | ₩61.07 Billion | -6.50% |
| 2021-12-31 | ₩65.31 Billion | +153.67% |
| 2020-12-31 | ₩25.75 Billion | +169.43% |
| 2019-12-31 | ₩9.56 Billion | -- |